Literature DB >> 27241794

Detection and treatment of atherosclerosis using nanoparticles.

Jia Zhang1, Yujiao Zu1, Chathurika S Dhanasekara1, Jun Li2, Dayong Wu3, Zhaoyang Fan4, Shu Wang1.   

Abstract

Atherosclerosis is the key pathogenesis of cardiovascular disease, which is a silent killer and a leading cause of death in the United States. Atherosclerosis starts with the adhesion of inflammatory monocytes on the activated endothelial cells in response to inflammatory stimuli. These monocytes can further migrate into the intimal layer of the blood vessel where they differentiate into macrophages, which take up oxidized low-density lipoproteins and release inflammatory factors to amplify the local inflammatory response. After accumulation of cholesterol, the lipid-laden macrophages are transformed into foam cells, the hallmark of the early stage of atherosclerosis. Foam cells can die from apoptosis or necrosis, and the intracellular lipid is deposed in the artery wall forming lesions. The angiogenesis for nurturing cells is enhanced during lesion development. Proteases released from macrophages, foam cells, and other cells degrade the fibrous cap of the lesion, resulting in rupture of the lesion and subsequent thrombus formation. Thrombi can block blood circulation, which represents a major cause of acute heart events and stroke. There are generally no symptoms in the early stages of atherosclerosis. Current detection techniques cannot easily, safely, and effectively detect the lesions in the early stages, nor can they characterize the lesion features such as the vulnerability. While the available therapeutic modalities cannot target specific molecules, cells, and processes in the lesions, nanoparticles appear to have a promising potential in improving atherosclerosis detection and treatment via targeting the intimal macrophages, foam cells, endothelial cells, angiogenesis, proteolysis, apoptosis, and thrombosis. Indeed, many nanoparticles have been developed in improving blood lipid profile and decreasing inflammatory response for enhancing therapeutic efficacy of drugs and decreasing their side effects. WIREs Nanomed Nanobiotechnol 2017, 9:e1412. doi: 10.1002/wnan.1412 For further resources related to this article, please visit the WIREs website.
© 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2016        PMID: 27241794      PMCID: PMC5133203          DOI: 10.1002/wnan.1412

Source DB:  PubMed          Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol        ISSN: 1939-0041


  184 in total

Review 1.  High-density lipoprotein--the clinical implications of recent studies.

Authors:  D J Gordon; B M Rifkind
Journal:  N Engl J Med       Date:  1989-11-09       Impact factor: 91.245

2.  EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions.

Authors:  Sylvie Marleau; Diala Harb; Kim Bujold; Roberta Avallone; Khadija Iken; Yanfei Wang; Annie Demers; Martin G Sirois; Maria Febbraio; Roy L Silverstein; André Tremblay; Huy Ong
Journal:  FASEB J       Date:  2005-08-25       Impact factor: 5.191

3.  Superparamagnetic iron oxide nanoparticles change endothelial cell morphology and mechanics via reactive oxygen species formation.

Authors:  Kivilcim Buyukhatipoglu; Alisa Morss Clyne
Journal:  J Biomed Mater Res A       Date:  2010-11-09       Impact factor: 4.396

4.  In vivo imaging of activated endothelium using an anti-VCAM-1 magnetooptical probe.

Authors:  Andrew Tsourkas; Vivek R Shinde-Patil; Kimberly A Kelly; Pratik Patel; Allison Wolley; Jennifer R Allport; Ralph Weissleder
Journal:  Bioconjug Chem       Date:  2005 May-Jun       Impact factor: 4.774

5.  Development of a magnetic resonance imaging protocol for the characterization of atherosclerotic plaque by using vascular cell adhesion molecule-1 and apoptosis-targeted ultrasmall superparamagnetic iron oxide derivatives.

Authors:  Carmen Burtea; Sébastien Ballet; Sophie Laurent; Olivier Rousseaux; Anne Dencausse; Walter Gonzalez; Marc Port; Claire Corot; Luce Vander Elst; Robert N Muller
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04-19       Impact factor: 8.311

6.  Atherosclerotic plaque composition: analysis with multicolor CT and targeted gold nanoparticles.

Authors:  David P Cormode; Ewald Roessl; Axel Thran; Torjus Skajaa; Ronald E Gordon; Jens-Peter Schlomka; Valentin Fuster; Edward A Fisher; Willem J M Mulder; Roland Proksa; Zahi A Fayad
Journal:  Radiology       Date:  2010-07-28       Impact factor: 11.105

7.  Detection of atherosclerotic lesions and intimal macrophages using CD36-targeted nanovesicles.

Authors:  Shufang Nie; Jia Zhang; Raul Martinez-Zaguilan; Souad Sennoune; Md Nazir Hossen; Alice H Lichtenstein; Jun Cao; Gary E Meyerrose; Ralph Paone; Suthipong Soontrapa; Zhaoyang Fan; Shu Wang
Journal:  J Control Release       Date:  2015-10-09       Impact factor: 9.776

Review 8.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I.

Authors:  Morteza Naghavi; Peter Libby; Erling Falk; S Ward Casscells; Silvio Litovsky; John Rumberger; Juan Jose Badimon; Christodoulos Stefanadis; Pedro Moreno; Gerard Pasterkamp; Zahi Fayad; Peter H Stone; Sergio Waxman; Paolo Raggi; Mohammad Madjid; Alireza Zarrabi; Allen Burke; Chun Yuan; Peter J Fitzgerald; David S Siscovick; Chris L de Korte; Masanori Aikawa; K E Juhani Airaksinen; Gerd Assmann; Christoph R Becker; James H Chesebro; Andrew Farb; Zorina S Galis; Chris Jackson; Ik-Kyung Jang; Wolfgang Koenig; Robert A Lodder; Keith March; Jasenka Demirovic; Mohamad Navab; Silvia G Priori; Mark D Rekhter; Raymond Bahr; Scott M Grundy; Roxana Mehran; Antonio Colombo; Eric Boerwinkle; Christie Ballantyne; William Insull; Robert S Schwartz; Robert Vogel; Patrick W Serruys; Goran K Hansson; David P Faxon; Sanjay Kaul; Helmut Drexler; Philip Greenland; James E Muller; Renu Virmani; Paul M Ridker; Douglas P Zipes; Prediman K Shah; James T Willerson
Journal:  Circulation       Date:  2003-10-07       Impact factor: 29.690

9.  Therapeutic siRNA silencing in inflammatory monocytes in mice.

Authors:  Florian Leuschner; Partha Dutta; Rostic Gorbatov; Tatiana I Novobrantseva; Jessica S Donahoe; Gabriel Courties; Kang Mi Lee; James I Kim; James F Markmann; Brett Marinelli; Peter Panizzi; Won Woo Lee; Yoshiko Iwamoto; Stuart Milstein; Hila Epstein-Barash; William Cantley; Jamie Wong; Virna Cortez-Retamozo; Andita Newton; Kevin Love; Peter Libby; Mikael J Pittet; Filip K Swirski; Victor Koteliansky; Robert Langer; Ralph Weissleder; Daniel G Anderson; Matthias Nahrendorf
Journal:  Nat Biotechnol       Date:  2011-10-09       Impact factor: 54.908

Review 10.  The M1 and M2 paradigm of macrophage activation: time for reassessment.

Authors:  Fernando O Martinez; Siamon Gordon
Journal:  F1000Prime Rep       Date:  2014-03-03
View more
  20 in total

Review 1.  From design to the clinic: practical guidelines for translating cardiovascular nanomedicine.

Authors:  Iwona Cicha; Cédric Chauvierre; Isabelle Texier; Claudia Cabella; Josbert M Metselaar; János Szebeni; László Dézsi; Christoph Alexiou; François Rouzet; Gert Storm; Erik Stroes; Donald Bruce; Neil MacRitchie; Pasquale Maffia; Didier Letourneur
Journal:  Cardiovasc Res       Date:  2018-11-01       Impact factor: 10.787

Review 2.  Iron Oxide Nanoparticles in Regenerative Medicine and Tissue Engineering.

Authors:  Ralf P Friedrich; Iwona Cicha; Christoph Alexiou
Journal:  Nanomaterials (Basel)       Date:  2021-09-08       Impact factor: 5.719

Review 3.  Nanotherapeutic Shots through the Heart of Plaque.

Authors:  Yogendra Kanthi; Adam de la Zerda; Bryan Ronain Smith
Journal:  ACS Nano       Date:  2020-01-27       Impact factor: 15.881

4.  Magnetic Nanoparticles Conjugated with Peptides Derived from Monocyte Chemoattractant Protein-1 as a Tool for Targeting Atherosclerosis.

Authors:  Chung-Wei Kao; Po-Ting Wu; Mei-Yi Liao; I-Ju Chung; Kai-Chien Yang; Wen-Yih Isaac Tseng; Jiashing Yu
Journal:  Pharmaceutics       Date:  2018-05-24       Impact factor: 6.321

5.  LncRNA TUG1 regulates ApoM to promote atherosclerosis progression through miR-92a/FXR1 axis.

Authors:  Liu Yang; Tie Li
Journal:  J Cell Mol Med       Date:  2020-06-28       Impact factor: 5.310

Review 6.  Targeting Inflammation With Nanosized Drug Delivery Platforms in Cardiovascular Diseases: Immune Cell Modulation in Atherosclerosis.

Authors:  Antonio Cervadoro; Roberto Palomba; Giuseppe Vergaro; Roberta Cecchi; Luca Menichetti; Paolo Decuzzi; Michele Emdin; Stefano Luin
Journal:  Front Bioeng Biotechnol       Date:  2018-11-27

7.  EGFP-EGF1-conjugated poly(lactic-co-glycolic acid) nanoparticles, a new diagnostic tool and drug carrier for atherosclerosis.

Authors:  Zhilin Wu; Chen Chen; Bo Zhang; Liang Tang; Wei Shi; Danying Liao; Gaohong Di; Jacques Rj Davis; Hui Wang
Journal:  Int J Nanomedicine       Date:  2019-04-11

8.  LDL‑induced NLRC3 inflammasome activation in cardiac fibroblasts contributes to cardiomyocytic dysfunction.

Authors:  Peng Wang; Wenbo Zhang; Zhen Feng; Jian Zhang; Ying Sun; Wei Zhang
Journal:  Mol Med Rep       Date:  2021-05-26       Impact factor: 2.952

Review 9.  Current Strategies for Microbubble-Based Thrombus Targeting: Activation-Specific Epitopes and Small Molecular Ligands.

Authors:  Zhaojian Wang; Huaigu Huang; Yuexin Chen; Yuehong Zheng
Journal:  Front Bioeng Biotechnol       Date:  2021-07-16

Review 10.  Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases.

Authors:  Yuao Wu; Karla X Vazquez-Prada; Yajun Liu; Andrew K Whittaker; Run Zhang; Hang T Ta
Journal:  Nanotheranostics       Date:  2021-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.